Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas - Wermke, Martin; Felip, Enriqueta; Gambardella, Valentina; Kuboki, Yasutoshi; Morgensztern, Daniel; Hamed, Zohra Oum'; Liu, Meiruo; Studeny, Matus; Owonikoko, Taofeek K; Institut Català de la Salut; [Wermke M] Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, Dresden, Germany. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Gambardella V] Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain. [Kuboki Y] Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. [Morgensztern D] Washington University School of Medicine, St. Louis, MO 63110, USA. [Hamed ZO] Boehringer Ingelheim France S.A.S., Reims, France; Vall d'Hebron Barcelona Hospital Campus (Future Oncology, 2022)